229 related articles for article (PubMed ID: 32654064)
1. Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients.
Woo MS; Steins D; Häußler V; Kohsar M; Haag F; Elias-Hamp B; Heesen C; Lütgehetmann M; Schulze Zur Wiesch J; Friese MA
J Neurol; 2021 Jan; 268(1):5-7. PubMed ID: 32654064
[No Abstract] [Full Text] [Related]
2. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
Creed MA; Ballesteros E; Jr LJG; Imitola J
Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Recovery Without B Cells or Antibodies in Patients Receiving Rituximab for Autoimmune Disease.
Zonozi R; Huizenga N; Charles R; Jeyabalan A; Niles JL
Iran J Kidney Dis; 2021 Mar; 1(2):159-160. PubMed ID: 33764328
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.
Shima A; Hamaguchi T; Tada Y; Yamada M
Intern Med; 2020 Jan; 59(1):121-124. PubMed ID: 31462595
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran.
Sahraian MA; Azimi A; Navardi S; Rezaeimanesh N; Naser Moghadasi A
Mult Scler Relat Disord; 2020 Sep; 44():102245. PubMed ID: 32512287
[No Abstract] [Full Text] [Related]
7. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Jeong IH; Joung A; Yeon JL; Dehmel T; Adams O; Kieseier BC; Kim HJ
J Neurol; 2015 Mar; 262(3):696-700. PubMed ID: 25559683
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
9. Capillary leak syndrome in neuromyelitis optica treated with rituximab.
Fuentes Fernandez I; Hernandez-Clares R; Carreón Guarnizo E; Meca Lallana JE
Mult Scler Relat Disord; 2017 Aug; 16():22-23. PubMed ID: 28755680
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Therapy in Neuromyelitis Optica: Moving Toward a Personalized Medicine Approach.
Tobin WO; Pittock SJ
JAMA Neurol; 2015 Sep; 72(9):974-7. PubMed ID: 26168370
[No Abstract] [Full Text] [Related]
11. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
Alldredge B; Jordan A; Imitola J; Racke MK
Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
[TBL] [Abstract][Full Text] [Related]
13. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
[TBL] [Abstract][Full Text] [Related]
15. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
16. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Hu Y; Nie H; Yu HH; Qin C; Wu LJ; Tang ZP; Tian DS
Autoimmun Rev; 2019 May; 18(5):542-548. PubMed ID: 30844555
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
19. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.
Diebold M; Müller S; Derfuss T; Décard BF
Mult Scler Relat Disord; 2019 Jun; 31():38-40. PubMed ID: 30901703
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
